Best GLP-1 Providers in Michigan (2026)

See by medication

Looking for a specific GLP-1? Browse Michigan providers by drug.

About GLP-1s in Michigan

Michigan allows telehealth GLP-1 prescriptions. Michigan Medicaid covers GLP-1s for both diabetes and obesity with prior authorization.

• •Michigan's adult obesity rate is 34.5%
• •Michigan Medicaid covers GLP-1s with prior authorization
• •Detroit is a major telehealth GLP-1 market in the Midwest

Top Cities for GLP-1 Treatment in Michigan

Telehealth providers ship to all Michigan addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the Michigan GLP-1 clinic directory →

GLP-1 Care Access in Michigan: The Numbers

Michigan has 991 NPI-registered in-person weight-management clinics across 162 cities — 13 with an obesity-medicine taxonomy, 381 endocrinology, and 606 bariatric — alongside 99 telehealth programs that ship to Michigan addresses. The cheapest verified ongoing compounded semaglutide price available to Michigan residents is $66/mo (tirzepatide: $97/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in Michigan

In Q1 2026, Michigan Medicaid reimbursed approximately $155,810,081 across 139,557 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in Michigan cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $199/mo.

For the exact criteria, drug list, and appeal process, read our Michigan Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in Michigan

According to CDC data, 34.5% of Michigan adults have obesity (BMI of 30 or higher). This places Michigan at #13 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping Michigan residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions